HOME   
Welcome

Vaxin Inc. is an emerging vaccine company using non-invasive means to elicit immune responses.   Our lead programs are vaccines to prevent disease caused by influenza (phase I), anthrax, Avian Influenza, Tetanus, and Alzheimer.

Our Technology

The Company’s proprietary technology consists of non-replicating adenovirus and bacterial vectors that can deliver antigens non-invasively (to the nasal passages or to the skin) to elicit a protective immune response. The nasal mucosa and the skin contain cells that participate in the body’s protection mechanism against disease causing pathogens. Vaxin’s technology harnesses this pre-existing feature of our immune system. CLICK FOR MORE INFORMATION

 

Awards

    Laureate of The Tech Museum Awards

    HERBERT L. HEYNEKER, PH.D., TO JOIN VAXIN’S BOARD OF DIRECTORS - May 4, 2010
    Press Release

    VAXIN RECEIVES BIRMINGHAM BUSINESS JOURNAL'S PACESETTER AWARD- April 27, 2010
    Press Release

    VAXIN CEO CREDITS FLU SCARE FOR ’09 GROWTH - April 22, 2010
    Birmingham Business Journal

    BIRMINGHAM BIOTECH FIRM VAXIN ADDS HEAVY INDUSTRY HITTERS TO BOARD - February 19, 2010
    Birmingham Business Journal

    VAXIN ANNOUNCES APPOINTMENTS TO BOARD OF DIRECTORS- February 19, 2010
    Press Release

    VAXIN DEAL MAY SIGNAL MATURATION OF BIRMINGHAM BIOTECH INDUSTRY - October 23, 2009
    Birmingham Business Journal

    VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA- October 14, 2009
    Press Release

    VAXIN PANDEMIC VACCINE PHASE I RELEASE- July 17, 2009
    Press Release

    VAXIN TECH 50 RELEASE- June 15, 2009
    Press Release

    WHAT'S ON THE HORIZON FOR A SWINE FLU VACCINE - May 6, 2009
    getbetterhealth.com

    VAXIN COMPLETES DOSING OF PHASE 1 HUMAN STUDY OF H5N1 PANDEMIC FLU VACCINE- February 24, 2009
    Press Release

    VAXIN AND CRUCELL ANNOUNCE COLLABORATION TO FIGHT ALZHEIMER’S DISEASE- November 13, 2008
    Press Release

    VAXIN TO PRESENT AT THE RODMAN & RENSHAW 1OTH ANNUAL HEALTHCARE CONFERENCE - November 5, 2008
    Press Release

    Vaxin begins pandemic flu study using Birmingham volunteers - October 8, 2008
    The Birmingham News

    VAXIN INITIATES PHASE I HUMAN STUDY OF H5N1 PANDEMIC FLU VACCINE - October 8, 2008
    Press Release

    VAXIN RECEIVES $100,000 GRANT FOR DEVELOPMENT OF ACNE VACCINE- September 18, 2008
    Press Release

    VAXIN AWARDED NIH FUNDING FOR AVIAN FLU VACCINE DEVELOPMENT- September 10, 2008 Press Release

    Vaxin developing game-changing flu vaccine - August 26, 2008
    TechJournal South

    VAXIN’S PANDEMIC VACCINE SPOTLIGHTED- August 13, 2008
    Press Release

    Biotech firm Vaxin taps new CEO, looks for VC funds - August 8, 2008
    Birmingham Business Journal

  TOP    
Home | About Us | Investor Information| Contact Us
Last modified: January 5, 2006
Copyright © 2001-2006 [Vaxin Inc]